Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma

Lechner, Matt; Takahashi, Yoko; Turri‐Zanoni, Mario; Liu, Jacklyn; Counsell, Nicholas; Hermsen, Mario; Kaur, Raman Preet; Zhao, Tianna; Ramanathan, Murugappan; Schartinger, Volker Hans; Emanuel, Oscar; Helman, Sam; Varghese, Jordan; Dudás, József; Riechelmann, Herbert; Sprung, Susanne; Haybaeck, Johannes; Howard, David; Engel, Nils W.; Stewart, Sarah; Brooks, Laura; Pickles, Jessica C.; Jacques, Thomas S.; Fenton, Tim R.; Williams, Luke; Vaz, Francis; O’Flynn, Paul; Stimpson, Paul; Wang, Shih-Yu; Hannan, Swarnali Ahmed; Unadkat, Samit; Hughes, Jonathan; Dwivedi, Raghav C.; Forde, Cillian T.; Randhawa, Premjit S; Gane, Simon; Joseph, J.; Andrews, Peter; Royle, G.; Franchi, Alessandro; Maragliano, Roberta; Battocchio, Simonetta; Bewicke-Copley, Helen; Pipinikas, Christodoulos P.; Webster, Amy P; Thirlwell, Chrissie; Ho, Debbie; Teschendorff, Andrew E.; Zhu, Tianyu; Steele, Christopher D.; Pillay, Nischalan; Vanhaesebroeck, Bart; Mohyeldin, Ahmed; Fernández-Miranda, Juan C.; Park, Ki Wan; Le, Quynh‐Thu; West, Robert B.; Saade, Rami E.; Manes, R. Peter; Omay, Sacit Bulent; Vining, Eugenia M.; Judson, Benjamin L.; Yarbrough, Wendell G.; Sansovini, Maddalena; Nicolini, Silvia; Grassi, Ilaria; Bongiovanni, Alberto; Capper, David; Schüller, Ulrich; Thavaraj, Selvam; Sandison, Ann; Šurda, Pavol; Hopkins, Claire; Ferrari, Marco; Mattavelli, Davide; Rampinelli, Vittorio; Facchetti, Fabio; Nicolai, Piero; Bossi, Paolo; Henriquez, Oswaldo A.; Magliocca, Kelly R.; Solares, C. Arturo; Wise, Sarah K.; Llorente, José Luís; Patel, Zara M.; Nayak, Jayakar V.; Hwang, Peter H.; Lacy, Peter D.; Woods, Robbie; O’Neill, James Paul; Jay, Amrita; Carnell, Dawn; Förster, Martin; Ishii, Masaru; London, Nyall R.; Bell, Diana; Gallia, Gary L.; Castelnuovo, Paolo; Severi, Stefano; Lund, Valerie J.; Hanna, Ehab Y.

doi:10.1016/j.ejca.2021.09.046

Cited by 30 publications

(37 citation statements)

References 45 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, esthesioneuroblastoma has favorable survival outcomes when compared with other sinonasal malignancies. 2 3 When selecting the optimal surgical approach, the surgeon must consider the approach that will allow for a negative margin resection and adequate reconstruction. In appropriately selected patients, endoscopic outcomes appear at least equivalent to open approaches and unilateral endoscopic approach may be used in select olfactory preservation cases.…”

Section: Discussionmentioning

confidence: 99%

“…Treatment consists of surgical resection with strong consideration for adjuvant treatment in advanced Kadish stage and high Hyams grade. 1 2 In the modern era, overall outcomes for esthesioneuroblastoma are favorable compared with many other sinonasal malignancies with 5-year overall survival estimated to be 80%. 2 3 …”

Section: Introductionmentioning

confidence: 99%

“… 1 2 In the modern era, overall outcomes for esthesioneuroblastoma are favorable compared with many other sinonasal malignancies with 5-year overall survival estimated to be 80%. 2 3 …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Esthesioneuroblastoma (Olfactory Neuroblastoma): Overview and Extent of Surgical Approach and Skull Base Resection

2022

View full text Add to dashboard Cite

Esthesioneuroblastoma is a rare malignancy originating from the olfactory epithelium. Treatment consists of surgical resection with strong consideration for adjuvant treatment in advanced Kadish stage and high Hyams grade. In the modern era, overall outcomes for esthesioneuroblastoma are favorable compared with many other sinonasal malignancies with 5-year overall survival estimated to be 80%. When selecting the optimal surgical approach, the surgeon must consider the approach that will allow for a negative margin resection and adequate reconstruction. In appropriately selected patients, endoscopic outcomes appear at least equivalent to open approaches and unilateral endoscopic approach may be used in select olfactory preservation cases.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Esthesioneuroblastoma (Olfactory Neuroblastoma): Overview and Extent of Surgical Approach and Skull Base Resection

2022

View full text Add to dashboard Cite

show abstract

“…Olfactory neuroblastoma or esthesioneuroblastoma develops in the olfactory cleft. Treatment is multimodal, including surgery in combination with postoperative RT [ 63 – 67 ]. For high-grade olfactory neuroblastoma (Hyams 3–4), induction ChT could be considered, followed by ChRT in case of good response [ 68 ].…”

Section: Surgical Strategy According To Histologymentioning

confidence: 99%

The Selective Role of Open and Endoscopic Approaches for Sinonasal Malignant Tumours

López

Shah

Beitler³

et al. 2022

Adv Ther

View full text Add to dashboard Cite

Endoscopic endonasal surgery has been demonstrated to be effective in the treatment of selected cases of sinonasal cancers. However, in cases of locally advanced neoplasms, as well as recurrences, the most appropriate approach is still debated. The present review aims to summarize the current state of knowledge on the utility of open approaches to resect sinonasal malignant tumours. Published comparative studies and meta-analyses suggest comparable oncological results with lower morbidity for the endoscopic approaches, but selection biases cannot be excluded. After a critical analysis of the available literature, it can be concluded that endoscopic surgery for selected lesions allows for oncologically safe resections with decreased morbidity. However, when endoscopic endonasal surgery is contraindicated and definitive chemoradiotherapy is not appropriate, craniofacial and transfacial approaches remain the best therapeutic option.

show abstract

“…Next-generation sequencing identified recurrent subtype-unique mutations including: APC , CTNNB1 , PIK3CA and KRAS in ITAC, EGFR and CDKN2A in SNSCC, NRAS and NF1 in MMM, IDH2 in SNUC, and ARID1A , SMARCB1 and SMARCA4 in SNEC, SNUC and TCS [ 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 ]. Other markers such as Somatostatin receptor 2 (SSTR2) expression were also reported in sinonasal cancers, such as in ONB [ 27 ]. Moreover, genetically well-characterized stable tumor cell lines, organoids and animal models are becoming available for the preclinical testing of candidate therapeutic agents [ 28 , 29 , 30 , 31 , 32 ].…”

mentioning

confidence: 99%

Sinonasal Cancer: Improving Classification, Stratification and Therapeutic Options

Hermsen

Bossi

Franchi

et al. 2023

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma

Cited by 30 publications

References 45 publications

Esthesioneuroblastoma (Olfactory Neuroblastoma): Overview and Extent of Surgical Approach and Skull Base Resection

Esthesioneuroblastoma (Olfactory Neuroblastoma): Overview and Extent of Surgical Approach and Skull Base Resection

The Selective Role of Open and Endoscopic Approaches for Sinonasal Malignant Tumours

Sinonasal Cancer: Improving Classification, Stratification and Therapeutic Options

Contact Info

Product

Resources

About